Company Overview - ADARx Pharmaceuticals, Inc. is a late-stage clinical biotechnology company focused on developing next-generation RNA therapeutics across various therapeutic areas [3] - The company aims to transform cutting-edge science into RNA medicines that address urgent unmet medical needs [3] Leadership Appointment - Laura Shawver, Ph.D., has been appointed as Chair of the Board of Directors, bringing 25 years of experience in the biopharma industry [1][2] - Dr. Shawver's leadership is expected to drive strategic growth and innovation in RNA therapeutics as the company advances its pipeline [2] Strategic Focus - ADARx is advancing a deep pipeline of RNA-targeted therapeutic candidates for diseases such as complement-mediated, genetic, cardiovascular, thrombosis, central nervous system, and metabolic diseases [3] - The company has a collaboration and license option agreement with AbbVie to develop small interfering RNA (siRNA) therapeutics across multiple disease areas, including neuroscience, immunology, and oncology [3]